Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)

该项目的目标是为国家毒理学计划(DNTP)司的活动提供支持，旨在预防因接触化学或物理制剂而引起的疾病或不良反应。该计划旨在评估早年接触化学品后的毒性。抗逆转录病毒疗法(ART)被推荐给所有艾滋病毒阳性者，包括孕妇。阿巴卡韦(ABC)/多洛替格列韦(DTG)/拉米夫定(3TC)是该项目中正在评估的一种ART，特别关注从怀孕第6天起至F1后代断奶期间每天服用ABC/DTG/3TC的F0母鼠的潜在心血管毒性，并再持续3个月。F1后代将在围产期暴露(妊娠和哺乳期转移)，但不直接服用。将在几个时间点评估F1和F0动物的心脏功能参数，以确定ABC/DTG/3TC暴露是否会导致心脏毒性。 关键词：艾滋病毒/艾滋病，人类免疫缺陷病毒感染，获得性免疫缺陷综合征，原发艾滋病毒，急性逆转录病毒综合征，无症状艾滋病毒，慢性艾滋病毒

The goal of this project is to provide support of the Division of the National Toxicology Program (DNTP) activities targeted toward the prevention of diseases or adverse effects caused by exposure to chemical or physical agents. This program is designed to evaluate toxicity following early life exposure to chemicals. Antiretroviral therapies (ART) are recommended for all HIV positive individuals including pregnant mothers. Abacavir (ABC) /dolutegravir (DTG)/lamivudine (3TC) is an ART under evaluation in the project with a specific focus on potential cardiovascular toxicity in F0 dams dosed daily with ABC/DTG/3TC from gestation day 6 through weaning of their F1 offspring, and for an additional 3 months. F1 offspring will be exposed perinatally (gestation and lactational transfer) but not directly dosed. Both F1 and F0 animals will be evaluated at several time points for functional cardiac parameters to determine if ABC/DTG/3TC exposure induces cardiotoxicity. Keywords: HIV/AIDS, Human immunodeficiency virus infection, acquired immune deficiency syndrome, primary HIV, acute retroviral syndrome, asymptomatic HIV, chronic HIV